Menu
Logo

Uptravi dosing vs efficacy

REFERENCES

1. Sitbon O, Channick R, Chin KM, et al; For the GRIPHON invitigator. Selexipag for the Treatment of Pulmonary Arterial Hypertensio.n. N Engl J Med. 2015; (suppl)373: 2522-33. https://www.nejm.org/doi/suppl/10.1056/NEJMoa1503184/suppl_file/nejmoa1503184_appendix.pdf . Accessed September 2020.

2. Uptravi Summary of Product Characteristics. Actelion Pharmaceuticals Ltd; 2017. https://www.ema. europa.eu/en/documents/product-information/uptravi-epar-product-information_en.pdf . Accessed September 2020.

CP-266808